Immune checkpoint blockade (ICB) is the strategy to block the binding of immune checkpoints to their cognate antigens, PD-L1 and B7/CD80, respectively, with the aim to reactivate T cells inside the tumor. This evidence concerns the gene CD274 and neoplasm.